InMode
INMD
Market cap $872M

14.31 USD

-0.23

1.58%

At close Jul 29, 4:00 PM EDT

After hours

14.30

-0.01

0.07%

1 day

-1.58%

5 days

-1.99%

1 month

-0.90%

3 months

-0.76%

6 months

-17.81%

Year to date

-15.63%

1 year

-20.54%

5 years

-10.73%

10 years

110.75%

About: InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.

Employees: 599

Healthcare Medical Devices

0

Funds holding %

of 7,323 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

11.32% more ownership

Funds ownership: 51.96% [Q4 2024] → 63.28% (+11.32%) [Q1 2025]

6% more capital invested

Capital invested by funds: $734M [Q4 2024] → $782M (+$47.5M) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

3% less first-time investments, than exits

New positions opened: 38 | Existing positions closed: 39

2% less funds holding

Funds holding: 247 [Q4 2024] → 243 (-4) [Q1 2025]

11% less repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 89

12% less call options, than puts

Call options by funds: $16.9M | Put options by funds: $19.2M

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$15

5%

upside

Avg. target

$19.50

36%

upside

High target

$24

68%

upside

2 analyst ratings

1 positive

50%

1 neutral

50%

0 negative

0%

Canaccord Genuity Caitlin Cronin	5%upside $15	Hold Maintained	11 Jul 2025
Barclays Matt Miksic	68%upside $24	Overweight Maintained	30 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about INMD published over the past 30 days

Zacks Investment Research

InMode (INMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

InMode (INMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

InMode: Margin Pressure, But Optionality Makes It Worth A Look

InMode's fundamentals remain strong despite guidance cuts, macro headwinds, and governance disputes, making current negative sentiment appear overdone. Valuation is compelling at just 9.3x forward EPS and ~6% FCF yield, with a robust cash buffer and capital-light business model offering downside protection. Share buybacks are accelerating, shrinking share count and compounding per-share value, even if revenues remain flat, providing a powerful catalyst for upside.

InMode: Margin Pressure, But Optionality Makes It Worth A Look

InMode to Report Second Quarter 2025 Financial Results and Hold Conference Call on July 30, Expects Q2 Revenue Between $95.4M-$95.5M, Decreases Full Year 2025 Revenue Guidance to be Between $365M-$375M

Conference call to be held on Wednesday, July 30, 2025, at 8:30 a.m. Eastern Time YOKNEAM, Israel, July 10, 2025 /PRNewswire/ -- InMode Ltd.

InMode to Report Second Quarter 2025 Financial Results and Hold Conference Call on July 30, Expects Q2 Revenue Between $95.4M-$95.5M, Decreases Full Year 2025 Revenue Guidance to be Between $365M-$375M

InMode Response Letter to DOMA by Moshe Mizrahy, CEO, Dated May 28, 2025

YOKNEAM, Israel , May 28, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today sent a letter to DOMA Perpetual Capital Management LLC ("DOMA") CEO and CIO Pedro Escudero in response to issues presented in his public letter dated May 9, 2025.

InMode Response Letter to DOMA by Moshe Mizrahy, CEO, Dated May 28, 2025

DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Resume Share Repurchase Program

Believes the Board Should Immediately Resume and Accelerate Buybacks Asserts Board Should Remove Moshe Mizrahy as CEO of the Company MIAMI , May 9, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to continue its stock repurchase program and to replace its CEO.

DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Resume Share Repurchase Program

InMode to Present at Upcoming Investor Conferences and Events

YOKNEAM, Israel , May 7, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences: BNP 3rd Annual Aesthetics Day Presenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer Format: Virtual fireside chat moderated by Navann Ty, Lead Equity Analyst and one-on-one meetings When: Monday, May 19, fireside chat at 11:00 am ET A live webcast of the presentation can be accessed here.

InMode to Present at Upcoming Investor Conferences and Events

InMode Granted Injunction Against Counterfeit Sales of Morpheus8 Radio Frequency Microneedling Devices and Needle Cartridges

IRVINE, Calif. , May 6, 2025 /PRNewswire/ -- InMode Ltd.

InMode Granted Injunction Against Counterfeit Sales of Morpheus8 Radio Frequency Microneedling Devices and Needle Cartridges

InMode Q1 Earnings: Short-Term Catalysts Have Vanished (Rating Downgrade)

InMode's Q1 2025 results disappointed, with revenue and EPS missing estimates, leading to a 12% stock drop and another potential guidance cut. Despite solid fundamentals and attractive valuation, weakening demand, no buybacks, and uncertain forecasts make me downgrade INMD from Buy to Hold. The company has high margins, lots of cash, and operates in a growing market, but short-term catalysts are lacking.

InMode Q1 Earnings: Short-Term Catalysts Have Vanished (Rating Downgrade)

InMode: Equity Value Hinges On Cash, Not Future Prospects (Rating Downgrade)

InMode's Q1 2025 earnings reveal a 3% YoY revenue decline and margin compression, signaling continued macroeconomic pressures and underutilization of installed platforms. Management's revised 2025 guidance lowers profitability expectations, reflecting ongoing challenges in the U.S. market and less profitable international expansion. Despite a strong balance sheet, past strategic missteps and ineffective cash allocation raise concerns about future shareholder value and growth prospects.

InMode: Equity Value Hinges On Cash, Not Future Prospects (Rating Downgrade)

Eyes On Park Introduces Revolutionary Envision by InMode System for Advanced Dry Eye Treatment in New York City

New York, New York--(Newsfile Corp. - April 28, 2025) - Eyes On Park, a leading optometry practice in Gramercy Park, announces the introduction of the cutting-edge Envision by InMode system for comprehensive dry eye treatment. Dr. Irina Shiyan and her team now offer this advanced, non-invasive technology that combines Forma-I radiofrequency and Lumecca-I intense pulsed light therapies to address the root causes of dry eye disease, not just the symptoms.

Eyes On Park Introduces Revolutionary Envision by InMode System for Advanced Dry Eye Treatment in New York City

See News Rankings

Charts implemented using Lightweight Charts™